ATE326479T1 - Varianten von antigenen des menschlichen papillomvirus - Google Patents

Varianten von antigenen des menschlichen papillomvirus

Info

Publication number
ATE326479T1
ATE326479T1 AT95941988T AT95941988T ATE326479T1 AT E326479 T1 ATE326479 T1 AT E326479T1 AT 95941988 T AT95941988 T AT 95941988T AT 95941988 T AT95941988 T AT 95941988T AT E326479 T1 ATE326479 T1 AT E326479T1
Authority
AT
Austria
Prior art keywords
variants
papilloma virus
human papilloma
virus antigens
hpv
Prior art date
Application number
AT95941988T
Other languages
English (en)
Inventor
Stirling John Edwards
John Cooper Cox
Elizabeth Ann Webb
Ian Frazer
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Ltd filed Critical Csl Ltd
Application granted granted Critical
Publication of ATE326479T1 publication Critical patent/ATE326479T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95941988T 1994-12-20 1995-12-20 Varianten von antigenen des menschlichen papillomvirus ATE326479T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPN0157A AUPN015794A0 (en) 1994-12-20 1994-12-20 Variants of human papilloma virus antigens

Publications (1)

Publication Number Publication Date
ATE326479T1 true ATE326479T1 (de) 2006-06-15

Family

ID=3784665

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95941988T ATE326479T1 (de) 1994-12-20 1995-12-20 Varianten von antigenen des menschlichen papillomvirus

Country Status (10)

Country Link
US (3) US6004557A (de)
EP (1) EP0796273B1 (de)
JP (1) JPH10510989A (de)
AT (1) ATE326479T1 (de)
AU (2) AUPN015794A0 (de)
CA (2) CA2207741C (de)
DE (1) DE69534995T2 (de)
NZ (1) NZ297946A (de)
WO (1) WO1996019496A1 (de)
ZA (1) ZA9510832B (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
HUP0003601A3 (en) 1997-08-05 2003-03-28 Stressgen Biotechnologies Corp Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
CA2313823A1 (en) 1997-12-10 1999-06-17 Csl Limited Porphorymonas gingivalis polypeptides and nucleotides
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
TR200002608T2 (tr) * 1998-03-09 2000-11-21 Smithkline Beecham Biologicals S.A Kombine aşı kompozisyonları
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
DE19819476C1 (de) * 1998-04-30 2000-01-05 Deutsches Krebsforsch Polypeptid mit immunogenen Eigenschaften und veränderten biologischen Funktionen eines Proteins
FR2781158B1 (fr) * 1998-07-15 2002-12-13 Vacs Internat Nouvelles proteines modifiees immunogenes non immunosuppressives, leur procede de preparation et leurs applications
AU766403C (en) * 1998-09-04 2004-05-27 Aventis Pasteur Limited Treatment of cervical cancer
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
KR100731820B1 (ko) 1998-10-05 2007-06-25 파멕사 에이/에스 치료적 백신화를 위한 새로운 방법
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
AU5926700A (en) 1999-07-08 2001-01-30 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
EP2100620A1 (de) * 1999-09-16 2009-09-16 Eisai Corporation of North America Polyepitop-Polypeptide kodierende Nukleinsäuren
AU2007201619B2 (en) * 1999-09-16 2011-05-12 Eisai Inc. Nucleic acids encoding polyepitope polypeptides
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
CA2408830A1 (en) * 2000-05-12 2001-11-22 The Regents Of The University Of California Treatment of human papillomavirus (hpv)-infected cells
KR100919266B1 (ko) 2000-06-26 2009-09-30 엔벤타 바이오파마슈티컬스 코포레이션 인간 파필로마 바이러스 치료법
US6841157B2 (en) 2000-07-07 2005-01-11 Merck & Co., Inc. Production of chimeric human papillomavirus
ES2724121T3 (es) 2000-12-08 2019-09-06 Academisch Ziekenhuis Leiden Péptidos largos de 22-45 residuos de aminoácidos que inducen y/o mejoran las respuestas inmunológicas específicas para antígenos
WO2002077012A2 (en) * 2001-03-23 2002-10-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human papilloma virus immunoreative peptides
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
DK1440085T3 (da) * 2001-10-18 2010-08-09 Medicyte Gmbh Transient immortalisering af celler af onkogene proteiner eller telomerase
FR2839072A1 (fr) * 2002-04-24 2003-10-31 Neovacs Produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, composition immunogene contenant ledit produit d'expression et son procede de preparation
US20040170606A1 (en) * 2002-06-07 2004-09-02 Palmer Kenneth E. Production of peptides in plants as viral coat protein fusions
US20050233307A1 (en) * 2002-09-12 2005-10-20 Kyle Gee Site-specific labeling of affinity tags in fusion proteins
CA2499837C (en) * 2002-10-03 2013-12-03 Wyeth Holdings Corporation Human papillomavirus polypeptides and immunogenic compositions
AU2003284239B2 (en) * 2002-10-21 2008-08-21 Eisai Inc. Compositions and methods for treating human papillomavirus-mediated disease
US7780992B2 (en) * 2002-12-08 2010-08-24 Tareq Abduljalil Albahri Antiviral medicament
KR100525321B1 (ko) * 2002-12-13 2005-11-02 안웅식 파필로마바이러스 항원 단백질 및ＣｐＧ-올리고데옥시뉴클레오타이드를 포함하는파필로마바이러스 유발 질환의 예방 또는 치료용 약제학적조성물
WO2004105681A2 (en) * 2003-04-28 2004-12-09 Innogenetics N.V. Cd4+ human papillomavirus (hpv) epitopes
ATE476528T1 (de) 2004-12-08 2010-08-15 Gen Probe Inc Nukleinsäuredetektion aus verschiedenen typen des humanen papillomavirus
US7314630B2 (en) * 2005-01-07 2008-01-01 Yao-Xiong Hu Compounds and methods of early diagnosis of cervical cancer and genital condyloma with HPV, CHSP60 tumor suppressor H-Ras, K-Ras and PTEN derived peptides modified
US20080267964A1 (en) * 2005-02-17 2008-10-30 Masaki Terabe Synergistic Effect of Tgf-Beta Blockade and Immunogenic Agents on Tumors
US8137674B2 (en) * 2006-04-19 2012-03-20 Postech Foundation Compositions comprising HPV polypeptides and immunoenhancement peptides for the treatment and prevention of cervical cancer
US20100055069A1 (en) * 2006-04-21 2010-03-04 Transgene S.A. Hpv-18-based papillomavirus vaccines
MX2008013488A (es) * 2006-04-21 2008-10-30 Transgene Sa Vacuna de virus de papiloma basado en hpv-16 (virus de papiloma humano 16).
KR102511874B1 (ko) * 2006-07-28 2023-03-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 백신 및 이의 사용 방법
CU23674A1 (es) 2007-07-31 2011-05-27 Ct Ingenieria Genetica Biotech Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
ES2655687T3 (es) 2009-09-11 2018-02-21 Proyecto De Biomedicina Cima, S.L. Composiciones terapéuticas para el tratamiento de enfermedades causadas por HPV
EP3730943B1 (de) 2010-04-08 2025-01-29 University of Pittsburgh - Of the Commonwealth System of Higher Education Zellenassay mit b-zellen-antigenen
WO2012020871A1 (ko) * 2010-08-13 2012-02-16 주식회사 제넥신 사람 파필로마바이러스 변형체 및 면역 증강제를 포함하는 자궁경부암 예방 또는 치료용 조성물
EP3533462A1 (de) 2011-12-21 2019-09-04 Vaccibody AS Impfstoffe gegen hpv
CN107073070A (zh) 2014-08-15 2017-08-18 格纳西尼有限公司 治疗宫颈癌的方法
JP5973007B2 (ja) * 2015-01-30 2016-08-17 ジェネクサイン・インコーポレーテッド ヒトパピローマウイルス変形体及び免疫増強剤を含む子宮頸癌の予防または治療用組成物
RU2017132190A (ru) 2015-03-18 2019-04-18 Омнисайт Гибридные белки, содержащие модифицированные поверхностные гликопротеины альфавируса и опухолеассоциированный антиген, и способы, связанные с ними
CN108601951B (zh) * 2015-12-09 2022-11-22 金港医疗(澳大利亚)私人有限公司 用于治疗的免疫调节组合物
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
WO2017144359A1 (en) 2016-02-22 2017-08-31 Boehringer Ingelheim Vetmedica Gmbh Method for the immobilization of biomolecules
US20180228885A1 (en) * 2016-03-04 2018-08-16 Orbis Health Solutions Llc Bacterial and viral vaccine strategy
UA127310C2 (uk) 2016-05-16 2023-07-19 Презідент Енд Феллоуз Оф Гарвард Колледж Спосіб очищення і активації ботулінічного нейротоксину
WO2018076008A1 (en) * 2016-10-21 2018-04-26 The Research Foundation For The State University Of New York Compositions and methods comprising permuted protein tags for facilitating overexpression, solubility, and purification of target proteins
WO2021205027A1 (en) 2020-04-09 2021-10-14 Vaccibody As Individualized therapeutic anticancer vaccine
MX2022013063A (es) 2020-04-24 2022-12-08 Genexine Inc Metodo para tratamiento del cancer cervicouterino.
WO2022238891A1 (en) * 2021-05-10 2022-11-17 Nikhil Goel Engineered cells for increased production of difficult-to-express proteins
WO2024181753A1 (ko) * 2023-02-27 2024-09-06 주식회사 마이크로유니 자가 증폭 rna 컨스트럭트 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593860A (en) * 1987-08-14 1997-01-14 Bio-Technology General Corp. Expression plasmids containing the deo promoter, and bacterial hosts containing the plasmids
DE4015044A1 (de) * 1990-05-10 1991-11-14 Behringwerke Ag Seroreaktive epitope auf proteinen des menschlichen papillomavirus (hpv) 18
AU8762991A (en) * 1990-09-26 1992-04-15 Bristol-Myers Squibb Company Human papilloma viral protein expression for use in vaccine compositions
JPH06503559A (ja) * 1990-12-12 1994-04-21 ザ・ユニバーシティ・オブ・クイーンズランド サブユニット・パピローマウイルス・ワクチンおよびそれに使用するペプチド
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
WO1992016638A1 (en) 1991-03-14 1992-10-01 5 Prime --> 3 Prime, Inc. Transduction vehicles for transferring dna to a mammalian cell
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein

Also Published As

Publication number Publication date
DE69534995T2 (de) 2007-01-11
JPH10510989A (ja) 1998-10-27
CA2419289A1 (en) 1996-06-27
AU693627B2 (en) 1998-07-02
US6004557A (en) 1999-12-21
NZ297946A (en) 2000-01-28
EP0796273B1 (de) 2006-05-17
AUPN015794A0 (en) 1995-01-19
DE69534995D1 (de) 2006-06-22
US6306397B1 (en) 2001-10-23
CA2207741A1 (en) 1996-06-27
WO1996019496A1 (en) 1996-06-27
US6303128B1 (en) 2001-10-16
EP0796273A4 (de) 2001-11-28
ZA9510832B (en) 1996-07-04
EP0796273A1 (de) 1997-09-24
AU4322996A (en) 1996-07-10
CA2207741C (en) 2003-04-22

Similar Documents

Publication Publication Date Title
EP0796273A4 (de) Varianten von antigenen des menschlichen papillomvirus
NO20000850D0 (no) Vaksine
CO5070644A1 (es) Vacunas que comprenden proteinas e6 de hpv y/o e7 de hpv junto con un oligonucleotido cpg como adyudante
DK0759935T3 (da) Rekombinant papillomavirus L1
ATE207495T1 (de) Peptide des menschlichen papillomavirus zur verwendung in zusammensetzungen, die eine menschliche t-zellreaktion induzieren
IL132468A0 (en) A kit for inducing immune response against a tumor or a disease caused by an infection agent
DK0585943T3 (da) Opløselige ligander for CD40
EA200400376A1 (ru) Пептиды, полученные из казеина, и их использование в терапии
WO2000075336A3 (fr) Fragment proteiques polyepitopiques des proteines e6 et e7 de hpv, leur obtention et leurs utilisations notamment en vaccination
ATE229978T1 (de) Helicobacter proteine und impstoffe
NO965590D0 (no) Polynukleotidvaksine for papillomavirus
CY1107571T1 (el) Αυξητικος παραγοντας νευρων ως βοηθητικη ουσια εμβολιου
DE59611189D1 (de) Vp-antigene des jc-virus
ATE198624T1 (de) Expression von albumin in hefe
FI931393A7 (fi) Peptidit käytettäväksi rokotuksessa ja neutraloivien vasta-aineiden in duktiossa ihmisen immuunikadon aiheuttavaa virusta vastaan
DK184186A (da) Terapeutisk praeparat til behandling af virussygdomme
DE3685651D1 (de) Den antigenischen und immunogenischen determinanten von wichtigen neutralisierenden proteinen des rotavirus entsprechende peptide.
EP0853486A4 (de) Therapeutische anwendungen von tierischen seren einschliesslich von pferdeseren in der behandlung von aids, krebs, und anderen viralen oder bakteriellen erkrankungen
AU4149699A (en) Use of inactivated immunosuppressive and/or angiogenic immunogenic proteins, preparation method and pharmaceutical or vaccine uses
ATE344052T1 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
DE69736779D1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
FR2792639B1 (fr) Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
ATE459248T1 (de) Tiermodell zur berechnung von impstoffen
RU93005036A (ru) Способ лечения вируса иммунодефицита человека

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties